We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Carel le Roux

Carel W. le Roux MBChB, MSc, FRCP, FRCPath, PhD

Co-Director, Metabolic Medicine Lab, Diabetes Complications Research Centre, Conway Institute, University College Dublin, Dublin, Ireland

Professor Carel le Roux graduated from medical school in Pretoria South Africa, completed his specialist training in metabolic medicine at St Bartholomew’s Hospitals and the Hammersmith Hospitals. He obtained his PhD from Imperial College London where he later took up a faculty position. He moved to University College Dublin for the Chair in Experimental Pathology and he is now a Director of the Metabolic Medicine Group. He currently coordinates an Innovative Medicine Initiative project on obesity. He previously received a President of Ireland Young Researcher Award, Irish Research Council Laurate Award, Clinician Scientist Award from the National Institute Health Research in the UK, and a Wellcome Trust Clinical Research Fellowship for his work on how the gut talks to the brain.

Disclosures

Professor le Roux serves on advisory boards for following companies: Consilient Health, NovoNordisk, Herbalife, Johnson & Johnson, ONO pharmaceuticals, Metronic, Fractyl, GI Dynamics, Roche, AstraZeneca, Lilly, and Boehringer Ingelheim.